Belgian ADC specialist ATB Therapeutics BV has kicked off with €54m from EQT Life Sciences and MRL Ventures Fun to push its payload technology towards clinical development.
Innate Pharma SAInnate Pharma SA has presented promising preclinical data of its tetraspecific antibody-based B and NK cell engager IPH6501, a novel approach to treat B cell non-Hodgkin lymphoma (B-NHL).
DiogenX SAThe French biotech company DiogenX is further strengthening its management team. In November, Dr Klara Owen was appointed as Chief Medical Officer.
AdaptimmuneAfter meeting the primary endpoints of a pivotal Phase II trial, UK-based Adaptimmune Ltd. is submitting an FDA Biologics License Application for its autologous T-cell receptor therapy (TCR-T) Lete-cel (letetresgene autoleucel).
Qiagen NVPharmahungary Group has announced it will be participating in a project aiming to set up standardised methods to examine intercellular and interorgan communication via extracellular vesicles, the next Big thing in the diagnosis and therapy of cancer and cardiovascular diseases
Alentis TherapeuticsSwiss Alentis Therapeutics has raised US$181.4m in an oversubscribed Series D financing set to boost clinical development of its anti-Claudin-1 ADCs in solid tumours.
EuroscreenFastThe study of G protein-coupled receptor (GPCR) signalling is crucial for understanding a wide range of physiological processes. Among the methods used to monitor calcium signalling, Aequorin stands out for its high sensitivity, specificity, and sub-cellular compartment targeting. While many CROs are still using fluorescent calcium dyes, EuroscreenFast is making use of Aequorin’s unique properties as an invaluable tool to delve into the complexities of cellular communication.
BIOCOMBiotech CSOs, CDMOs, CROs, lab specialists and AI developers gave an in-depth insight into next-generation antibody-based therapies to about 1,500 attendees at the 16th PEGS Europe in Barcelona. Several new formats are expected to enter the market in the next few years, promising to significantly reduce the side effects of CAR-Ts, bispecific antibodies, ADCs, etc. and improve their efficacy.
Memorial Sloan Kettering Cancer CentreUS spin-out of German MPI for molecular genetics, Harbinger Health Inc, has started a collaboration with Memorial Sloan Kettering Cancer Centre to turboboost recruiting for its Core-HH study. The study aims to validate a blood test that predicts tumour developement in cancer stage I.
Novo NordiskNovo Nordisk is putting down up to US$362m to tap into Ascendis’ TransCon technology for treatments in metabolic and cardiovascular diseases. The pharma powerhouse has its sights set on developing a once-monthly GLP-1 receptor agonist.